Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1282358

registered interest
date	01/02/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Biotechnology
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what plans they have to undertake a strategic review of the role biologics manufacturing could play in pandemic responsiveness and resilience.
tabling member printed	Lord Walney
uin	HL12874
answer	answer is ministerial correction date of answer 15/02/2021 answer text <p>Currently the UK does not have the capability or scale to manufacture bulk levels of antibodies; the Vaccine Taskforce identified this as a potential weakness in the UK’s future pandemic response.</p><p> </p><p>As a result, the Government issued a Prior Information Notice in October 2020 to engage with the market to explore how UK antibody manufacturing capability can be developed to secure permanent UK access and build resilience. The findings from the market engagement exercise, and the wider landscape of the pandemic, has resulted in the need for a broader strategic review of the role that biologics manufacturing could play in pandemic responsiveness and resilience.</p><p><strong> </strong></p><p>The Government has invested over £300 million to secure and scale-up the UK’s vaccine manufacturing capabilities to be able to respond to the pandemic. This includes:</p><p> </p><p>a) Facilities that have come online:</p><ul><li>£4.7 million for skills training through the Advanced Therapies Skills Training Network, which will be delivered through both virtual and physical centres;</li><li>£8.75 million for the set-up of the rapid deployment facility at Oxford Biomedica in Oxfordshire;</li><li>£65.5 million for the early manufacture of the University of Oxford / AstraZeneca vaccine; and</li><li>Funding for fill and finish through a contract with Wockhardt in Wrexham, North Wales which is currently providing fill and finish capabilities to the University of Oxford / AstraZeneca vaccine.</li></ul><p> </p><p>b) Facilities that will come online later this year, to help provide longer term UK capacity and will help in pandemic preparedness:</p><p> </p><ul><li>£93 million to accelerate the completion and expanded role of the Vaccine Manufacturing Innovation Centre in Oxfordshire; and</li><li>£127 million for the Cell and Gene Therapy Catapult Braintree in Essex.</li></ul><p> </p><p>In addition to the above, we have also funded the expansion of the Valneva factory in Livingston, Scotland.</p> answering member printed Lord Callanan question first answered 15/02/2021 15:38:18 answering member 4336 label Biography information for Lord Callanan
tabling member	3917 label Biography information for Lord Walney

1141564

registered interest
date	23/07/2019
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Biotechnology
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what steps they are taking to help increase growth in the UK biotechnology sector after Brexit.
tabling member printed	Lord Taylor of Warwick
uin	HL17432
answer	answer is ministerial correction date of answer 01/08/2019 answer text <p>Data published by the UK BioIndustry Association (BIA) and Informa Pharma Intelligence in January 2019 showed that a record £2.2bn was raised by UK-based biotech companies in 2018, compared to £1.2bn in 2017.</p><p> </p><p>The Government is committed to supporting the continued success of the UK’s knowledge intensive sectors, including the biotechnology. The first and second Life Sciences Sector Deals have reiterated the Government’s commitment to unlock over £20 billion of patient capital investment over 10 years and increase the UK’s R&amp;D spend to reach 2.4% of GDP by 2027.</p><p> </p><p>In addition to this, our recent UK Bioeconomy Strategy sets out a framework for how government, industry and academia can work together to capitalise on our world class research, development and innovation base to grow the bioeconomy. Applying our expertise in bioscience and biotechnology across multiple industry sectors can achieve clean growth and deliver real, measurable benefits for the UK economy.</p><p> </p> answering member printed Lord Duncan of Springbank question first answered 01/08/2019 13:01:39 answering member 4686 label Biography information for Lord Duncan of Springbank
tabling member	1796 label Biography information for Lord Taylor of Warwick

1077134

registered interest
date	25/02/2019
answering body	Treasury
answering dept id	14
answering dept short name	Treasury
answering dept sort name	Treasury
hansard heading	Biotechnology
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Chancellor of the Exchequer, what assessment he has made of the implications for his policies of the BioIndustry Association report entitled Confident capital: backing U.K. biotech, published on 1 January 2019; and what steps he is taking to help ensure that 2019 is a successful year for the U.K. biotechnology sector.
tabling member constituency	Cambridge
tabling member printed	Daniel Zeichner
uin	225533
answer	answer is ministerial correction date of answer 05/03/2019 answer text <p>We welcome the BioIndustry Association report, which the Government launched at the BioIndustry Association’s event, Strategic Technologies in Life Sciences: The Future is Now, attended by myself on 24 January 2018. The Government is proactively supporting the UK’s strong life sciences sector.</p><p> </p><p>The Government has published two Life Sciences Sector Deals, which are supported by the Government’s commitment to delivering the biggest increase in R&amp;D investment for 40 years. Since Autumn 2016, Government has committed an additional £7 billion in R&amp;D by 2021-22, demonstrating clear progress towards the Government’s ambition to raise investment in R&amp;D in the economy to 2.4% of GDP by 2027.</p><p> </p><p>At Budget 2017 the Government also announced a 10-year action plan to unlock over £20bn to finance growth in innovative firms, including life science companies.</p><p> </p> answering member constituency Newark answering member printed Robert Jenrick question first answered 05/03/2019 16:06:42 answering member 4320 label Biography information for Robert Jenrick
tabling member	4382 label Biography information for Daniel Zeichner

1020428

registered interest
date	05/12/2018
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Biotechnology
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, when he plans to publish the bioeconomy sector deal.
tabling member constituency	Bristol East
tabling member printed	Kerry McCarthy
uin	199342
answer	answer is ministerial correction date of answer 11/12/2018 answer text <p>Several sectors, including the bioeconomy sector, have expressed an interest in a Sector Deal. We intend to take forward further Deals that best meet expectations set out in the White Paper in due course. I am pleased to say that on 5th December 2018 the UK’s first Bioeconomy Strategy was published on GOV.UK, to provide a framework for growth to 2030.</p> answering member constituency Watford answering member printed Richard Harrington question first answered 11/12/2018 17:37:57 answering member 4068 label Biography information for Lord Harrington of Watford previous answer version 91123 answering member constituency Watford answering member printed Richard Harrington answering member 4068 label Biography information for Lord Harrington of Watford
tabling member	1491 label Biography information for Kerry McCarthy

1002217

registered interest
date	05/11/2018
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Biotechnology
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government when the bio-economy sector deal will be published.
tabling member printed	Baroness Featherstone
uin	HL11238
answer	answer is ministerial correction date of answer 19/11/2018 answer text <p>Several sectors have expressed an interest in a Sector Deal. We intend to take forward some further Deals that best meet expectations set out in the White Paper in due course.</p> answering member printed Lord Henley question first answered 19/11/2018 17:54:23 answering member 2616 label Biography information for Lord Henley
tabling member	1531 label Biography information for Baroness Featherstone

101760

registered interest
date	30/10/2014
answering body	Department for Business, Innovation and Skills
answering dept id	26
answering dept short name	Business, Innovation and Skills
answering dept sort name	Business, Innovation and Skills
hansard heading	Biotechnology
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Innovation and Skills, what steps his Department is taking to promote the UK as a location of choice for life science investment in trade missions.
tabling member constituency	Salisbury
tabling member printed	John Glen
uin	212638
answer	answer is ministerial correction date of answer 07/11/2014 answer text <p>The Life Sciences Organisation (LSO), sitting within UK Trade and Investment (UKTI), is responsible for promoting the UK as an investment destination for life sciences, as well as supporting UK companies to increase exports to other markets. The team comprises a mixture of industry specialists and experienced civil servants, who together provide a range of support to potential investors and exporters.</p><p> </p><p>The LSO has developed a suite of marketing materials that showcase the UK’s life sciences capabilities across a number of priority sub-sectors, including but not limited to pharmaceutical manufacturing, regenerative medicine and experimental medicine &amp; clinical trials. Within each theme the LSO promotes the UK through direct, in-market company visits and/or tailored events and activities around the world, and works with international companies that would be well placed to take advantage of the UK offer. In 2013/14, the Life Sciences Organisation delivered 136 FDI projects creating or safeguarding more than 3,500 jobs.</p><p> </p> answering member constituency West Suffolk answering member printed Matthew Hancock question first answered 07/11/2014 14:43:43 answering member 4070 label Biography information for Matt Hancock
tabling member	4051 label Biography information for John Glen

101761

registered interest
date	30/10/2014
answering body	Department for Business, Innovation and Skills
answering dept id	26
answering dept short name	Business, Innovation and Skills
answering dept sort name	Business, Innovation and Skills
hansard heading	Biotechnology
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Innovation and Skills, what estimate he has made of the number of jobs in each region and constituent part of the UK which are supported by the life science industry.
tabling member constituency	Salisbury
tabling member printed	John Glen
uin	212639
answer	answer is ministerial correction date of answer 07/11/2014 answer text <p>There are no published official statistics on the regional distribution of life science industry jobs. The table below includes an estimate of employment in 2013 in companies active in three “health life science” sectors: Medical Biotechnology, Medical Technology and Pharmaceuticals, by region and by constituent part of the UK, obtained from the Bioscience and Health Technology company database used by the Office for Life Sciences. The figures are based on locations of active sites for which employment figures can be obtained. They do not include those employed by public or third sector organisations nor employment in companies whose main activity falls outside life sciences, including indirect suppliers to the sector.</p><p> </p><table><tbody><tr><td> </td><td><p><strong>Number of employees in health life science industry ‘000s 2013</strong></p></td></tr><tr><td><p>East Midlands</p></td><td><p>9.5</p></td></tr><tr><td><p>East of England</p></td><td><p>28.8</p></td></tr><tr><td><p>Greater London</p></td><td><p>13.6</p></td></tr><tr><td><p>North East England</p></td><td><p>7.1</p></td></tr><tr><td><p>North West England</p></td><td><p>17.0</p></td></tr><tr><td><p>South East England</p></td><td><p>36.8</p></td></tr><tr><td><p>South West England</p></td><td><p>8.2</p></td></tr><tr><td><p>West Midlands</p></td><td><p>14.5</p></td></tr><tr><td><p>Yorkshire and the Humber</p></td><td><p>13.5</p></td></tr><tr><td><p>England total</p></td><td><p>149.0</p></td></tr><tr><td> </td><td> </td></tr><tr><td><p>Northern Ireland</p></td><td><p>4.3</p></td></tr><tr><td><p>Scotland</p></td><td><p>11.5</p></td></tr><tr><td><p>Wales</p></td><td><p>9.1</p></td></tr><tr><td><p>UK Total</p></td><td><p>173.9</p></td></tr></tbody></table><p>Source: Bioscience and Health Technology database, an annual summary of the data was published as “Strength and Opportunity 2013, the landscape of the medical technology, medical biotechnology, industrial biotechnology and pharmaceutical sectors in the UK”</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 07/11/2014 16:53:00 answering member 4020 label Biography information for George Freeman
tabling member	4051 label Biography information for John Glen

101774

registered interest
date	30/10/2014
answering body	Department for Business, Innovation and Skills
answering dept id	26
answering dept short name	Business, Innovation and Skills
answering dept sort name	Business, Innovation and Skills
hansard heading	Biotechnology
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Innovation and Skills, what comparative assessment he has made of the competitiveness of the (a) UK, (b) France, (c) Germany, (d) China and (e) US life science industry.
tabling member constituency	Salisbury
tabling member printed	John Glen
uin	212635
answer	answer is ministerial correction date of answer 11/11/2014 answer text <p>The UK pharmaceutical sector contributes more than £13 billion to UK Gross Value Added (GVA), making it the second largest in Europe after Germany measured by GVA. The life sciences sector employs 173,900 people in the UK, and the UK is second only to the US measured by the share of top 1% citations in life science related subjects. The Office of Life Sciences is currently developing a set of indicators reflecting the broad competitiveness of the UK life science environment against key international comparators.</p><p> </p><p>More broadly, the most recent Global Competitiveness Report by the World Economic Forum (WEF) overall ranks the UK within the top 10 competitive countries in which to conduct business, continuing its historical strong performance. The UK is well regarded for its high quality science and research base, high-level skills, openness to international trade and effectiveness of its regulatory and competition regimes and flexible labour market. As a result the UK overall remains a magnet for inward investment, second only to the USA.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 11/11/2014 12:46:09 answering member 4020 label Biography information for George Freeman
tabling member	4051 label Biography information for John Glen

101775

registered interest
date	30/10/2014
answering body	Department for Business, Innovation and Skills
answering dept id	26
answering dept short name	Business, Innovation and Skills
answering dept sort name	Business, Innovation and Skills
hansard heading	Biotechnology
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Innovation and Skills, what structures his Department has in place to ensure that (a) the Life Sciences Organisation and (b) the Office for Life Sciences co-ordinate with the MHRA and National Institute of Health and Care Excellence.
tabling member constituency	Salisbury
tabling member printed	John Glen
uin	212636
answer	answer is ministerial correction date of answer 11/11/2014 answer text <p>Since April 2014 the Office for Life Sciences (OLS) has operated as a joint Director-led unit between the Department of Business Innovation and Skills and the Department of Health. The previous good working relationships between the OLS and MHRA and NICE have been strengthened through this move, as all these bodies are now either part of or sponsored by the Department of Health and all three fall within my Ministerial portfolio.</p><p> </p><p>The UKTI Life Sciences Organisation (LSO) also has strong working relationships with MHRA and NICE, both directly and through the OLS, largely operating on an informal basis rather than within particular structures.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 11/11/2014 11:48:16 answering member 4020 label Biography information for George Freeman
tabling member	4051 label Biography information for John Glen